VANCOUVER, BC / ACCESS Newswire / November 4, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...
MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...
Asianet Newsable on MSN
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug
The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of ...
Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...
Having a higher BMI at diagnosis is tied to faster disability progression in people with multiple sclerosis, according to a ...
BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...
Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial ...
The breakdown of myelin, the insulating layer around brain cells that supports brain function, is prevalent in a range of ...
Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.
Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Prepa ...
The field of biotechnology has always transformed cutting-edge science into life-changing medicines, but today that transformation is happening at a staggering pace.
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback